(Q34627908)

3 August 2017

1 reference

title

Drugs as P-glycoprotein substrates, inhibitors, and inducers (English)

1 reference

3 August 2017

Richard B Kim

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

3 August 2017

published in

Drug Metabolism Reviews

1 reference

3 August 2017

volume

34

1 reference

3 August 2017

issue

1-2

1 reference

3 August 2017

page(s)

47-54

1 reference

Biochemical, cellular, and pharmacological aspects of the multidrug transporter

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Genetic analysis of the multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Biochemistry of multidrug resistance mediated by the multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

P-Glycoprotein, a gatekeeper in the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

The subpopulation of CF-1 mice deficient in P-glycoprotein contains a murine retroviral insertion in the mdr1a gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

P-glycoprotein-mediated transcellular transport of MDR-reversing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Bromocriptine modulates P-glycoprotein function

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Brain bilirubin content is increased in P-glycoprotein-deficient transgenic null mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Modulation of P-glycoprotein activity by glial factors and retinoic acid in an immortalized rat brain microvessel endothelial cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Adenosine triphosphate-dependent transport of estradiol-17beta(beta-D-glucuronide) in membrane vesicles by MDR1 expressed in insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Decreased biotolerability for ivermectin and cyclosporin a in mice exposed to potent P‐glycoprotein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Resistance to tetracycline, a hydrophilic antibiotic, is mediated by P-glycoprotein in human multidrug-resistant cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FDMR-120001389

21 January 2018

Identifiers

DOI

10.1081/DMR-120001389

1 reference

3 August 2017

1 reference